Inhibition of replication of hepatitis B virus by cytallene in vitro

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1755-1760

  Zhu, Yong Lian ^a   Pai, S Balakrishna ^a   Liu, Shwu Huey ^a   Grove, Kristie L ^a   Jones, Bryan C N M ^b   Simons, Claire ^b   Zemlicka, Jiri ^b   Cheng, Yung Chi ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CYTALLENE; CYTIDINE DERIVATIVE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; ENANTIOMER; HEPATITIS B VIRUS; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0030802951     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1755     Document Type: Article

References (26)

1. Beasley, R. P. 1988. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
2. Chang, C.-N., S.-L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C.-H. Tsai, Y.-C. Cheng, D. Liotla, and R. Schinazi. 1992. Deoxycytidine deaminase-resistant stercoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
3. Chen, C. H., and Y.-C. Cheng. 1989. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264:11934-11937.
4. Cheng, Y.-C., B. Domin, and L.-S. Lee. 1977. Human deoxycytidine kinase. Purification and characterization of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia patients. Biochim. Biophys. Acta 481:481-492.
5. Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, and W. J. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299.
6. Chu, C. K., T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, S. B. Pai, G.-Q. Yao, J.-P. Sommadossi, and Y.-C. Cheng. 1995. Use of 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob. Agents Chemother. 39:979-981.
7. Dienstag, J. L., R. P. Perrillo, E. R. Schiff, M. Bartholomew, C. Vicary, and M. Rubin. 1995. A preliminary trial of lamivudine for the chronic hepatitis B infection. N. Engl. J. Med. 333:1657-1661.
8. Doong, S.-L., C.-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
9. Eriksson, S., B. Kierdaszuk, B. Munch-Petersen, B. Oberg, and N.-G. Johansson. 1991. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogues. Biochem. Biophys. Res. Commun. 176:586-592.
10. Eron, J. J., S. L. Benoit, J. Jemsek, R. D. MacArthur, J. Santana, J. B. Quinn, D. R. Kuritzkes, M. A. Fallon, and M. Rubin. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
11. Furman, P. A., J. E. Wilson, J. E. Reardon, and G. R. Painter. 1995. The effect of absolute configuration on the anti-HIV and anti-HBV activity of nucleoside analogues. Antiviral Chem. Chemother. 6:345-355.
12. Ganem, D. 1982. Persistent infection of humans with hepatitis B virus: mechanism and consequences. Rev. Infect. Dis. 4:1026-1047.
13. Gosselin, G., R. F. Schinazi, J.-P. Sommadossi, C. Mathé, M.-C. Bergogne, A.-M. Aubertin, A. Kirn, and J.-L. Imbach. 1994. Anti-human immunodeficiency virus activities of the β-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1292-1297.
14. Hayashi, S., S. Phadtare, J. Zemlicka, M. Matsukura, H. Mitsuya, and S. Broder. 1988. Adenallene and cytallene: acyclic nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA 85:6127-6131.
15. Hayashi, S., S. Phadtare, J. Zemlicka, M. Matsukura, H. Mitsuya, and S. Broder. 1989. Adenallene and cytallene, two novel acyclic nucleoside derivatives active against human immunodeficiency virus (HIV) in T-cells and monocytes/macrophages in vitro: further characterization of anti-viral and cytotoxic activity, p. 371-383. In Mechanisms of action and therapeutic applications of biologicals in cancer and immune deficiency disorders. Alan R. Liss, Inc., New York, N.Y.
16. 4-acyl-cytallenes. J. Med. Chem. 38:1397-1405.
17. Kim, H. O., K. Shanmuganathan, A. J. Alves, L. S. Jeong, J. W. Beach, R. F. Schinazi, C.-N. Chang, Y.-C. Cheng, and C. K. Chu, 1992. Potent anti-HIV and anti-HBV activities of (-)-L-β-dioxolane-C and (+)-L-β-dioxolane-T and their asymmetric synthesis. Tetrahedron Lett. 33:6899-6902.
18. Lee, L.-S., and Y.-C. Cheng. 1976. Human deoxythymidine kinase I. Purification and general properties of the cytoplasmic and mitochondrial isozymes derived from blast cells of acute myelocytic leukemia. J. Biol. Chem. 251: 2600-2604.
19. Lin, T.-S., M.-Z. Luo, M.-C. Liu, S. B. Pai, G. E. Dutschman, and Y.-C. Cheng. 1994. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and human hepatitis B virus (HBV). J. Med. Chem. 37:798-803.
20. Lin, T.-S., M.-Z. Luo, M.-C. Liu, S. B. Pai, G. E. Dutschman, and Y.-C. Cheng. 1994. Antiviral activity of 2′,3′-dideoxy-β-L-5-fluorocytidine (β-L-FddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:171-174.
21. Lin, T.-S., M.-Z. Luo, M.-C. Liu, Y.-L. Zhu, E. Gullen, G. E. Dutschman, and Y.-C. Cheng. 1996. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine(β- L-d4C) and 2′,3′-dideoxy-2'.3'-didehydro-ß-L-5-fiuorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent inhibitors of human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1757-1759.
22. Pai, S. B., S.-H. Liu, Y.-L. Zhu, C. K. Chu, and Y.-C. Cheng. 1996. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-β-L-arabinofuranosyl uracil. Antimicrob. Agents Chemother. 40:380-386.
23. Phadtare, S., and J. Zemlicka. 1989. Nucleic acid derived allenols: unusual analogues of nucleosides with antiretroviral activity. J. Am. Chem. Soc. 111:5925-5931.
24. Simons, C., S. Chokekijchai, H. Mitsuya, and J. Zemlicka. 1994. Synthesis and anti-HBV activity of 5-fluorocytallene: N-dimethylaminomethylene as a facilitating group in acetylene-allene isomerization. Nucleosides Nucleotides 13:1779-1789.
25. Tipples, G. A., M. M. Ma, K. P. Fischer, V. G. Bain, N. M. Kneteman, and D. L. Tyrrell. 1996. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24:714-717.
26. Tyrrell, D. L. J., K. Fischer, K. Sayani, W. Tan, and L. Jewell. 1993. Treatment of chimpanzees and ducks with lamivudine, 2′,3′-dideoxy-3′-thiacytidine results in a rapid suppression of hepadnaviral DNA in sera. Clin. Invest. Med. 16:B77.